First US Lucentis Biosimilar Expected By Year End, Roche Confirms
Samsung Bioepis’ SB11 Biosimilar Pending With FDA
Another of Roche’s biologic blockbusters is due to bite the dust this year, the originator has confirmed, with biosimilar competition to Lucentis forecast in the second half of 2021.
You may also be interested in...
Roche insisted that “biosimilar competition is only one factor in the overall picture,” as it reported another set of depleted figures for its three powerhouse biologic brands: Avastin, MabThera/Rituxan and Herceptin.
In the month ahead, Viatris may land history-making FDA biosimilar approvals, while readers will enjoy Generics Bulletin’s usual close coverage of the quarterly financial reports.
Hot on the heels of Samsung Bioepis receiving an EMA endorsement for its Byooviz version, Xbrane Biopharma has laid out plans for its own ranibizumab biosimilar, Xlucane, to be filed in both the EU and the US following positive Phase III results.